首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   19707篇
  免费   3321篇
  国内免费   2323篇
化学   13694篇
晶体学   177篇
力学   1130篇
综合类   118篇
数学   2734篇
物理学   7498篇
  2024年   86篇
  2023年   430篇
  2022年   652篇
  2021年   704篇
  2020年   850篇
  2019年   773篇
  2018年   699篇
  2017年   665篇
  2016年   985篇
  2015年   964篇
  2014年   1098篇
  2013年   1474篇
  2012年   1688篇
  2011年   1758篇
  2010年   1230篇
  2009年   1108篇
  2008年   1260篇
  2007年   1105篇
  2006年   983篇
  2005年   884篇
  2004年   703篇
  2003年   617篇
  2002年   686篇
  2001年   543篇
  2000年   438篇
  1999年   429篇
  1998年   342篇
  1997年   311篇
  1996年   330篇
  1995年   291篇
  1994年   232篇
  1993年   163篇
  1992年   165篇
  1991年   159篇
  1990年   123篇
  1989年   94篇
  1988年   54篇
  1987年   56篇
  1986年   73篇
  1985年   48篇
  1984年   32篇
  1983年   26篇
  1982年   15篇
  1981年   11篇
  1980年   4篇
  1976年   1篇
  1975年   2篇
  1974年   1篇
  1969年   1篇
  1957年   4篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
The 222Rn emanation fraction (EF) released from the technically enhanced naturally occurring radioactive material (TE-NORM) wastes at certain sites of petroleum and gas production was determined. The samples were analyzed by γ-ray spectrometry to determine the activity concentration of the 226Ra content, of which the 222Rn emanation fraction was calculated. The results showed that the 222Rn emanation fraction differs in the oil and gas production sites and it is independent of the activity concentration of 226Ra. This revised version was published online in August 2006 with corrections to the Cover Date.  相似文献   
132.
A procedure for the Raman spectra calculation of vitreous and molten silicates was presented in this paper. It includes molecular dynamics MD simulation for the generation of equilibrium configurations, Wilson's GF matrix method for the calculations of eigenfrequencies and corresponding vectors, electro-optical parameters method (EOPM) for the Raman intensity calculations, and the bond polarizability model (BPM) for the determination of polarizability and polarizability derivative. One of the most important characteristics of this procedure is the achievement of the partial Raman spectra of five tetrahedral units, as well as the total spectral envelope. In this paper, the calculation was carried out for the vitreous and molten calcium silicates with different compositions and at various temperatures. It is worthwhile to note that the calculation is based on statistical configurations distribution in the space and so it is not needed to artificially adjust the full width at half maximum (FWHM) of spectra. It was also tested through the good agreement of the calculated spectra with the experimental, including some regularity of spectral properties. According to the calculation, the symmetrical stretching of whole tetrahedral units, to which the stretching of Si-O(nb) bond gives the main contribution to intensity, is proven to be the dominance in the high-frequency range (800-1200 cm(-1)) and the symmetrical bending of Si-O(b)-Si, to which the stretching of Si-O(b) bond exhibits the main contribution, is the dominance in the medium-frequency range (400-700 cm(-1)). As the first theoretical results, the Raman scattering coefficient of each Q(i) was found little change along with the variation of composition and temperature.  相似文献   
133.
二烷基二硫代氨基甲酸基作为良好的双齿配体较易与过渡金属生成高配位的配合物,含有环戊二烯基的高配位钛、锆、铪配合物的研究相继出现[1-5],这类七配位、18-电子构型的配合物是立体化学刚性,具有独特的光谱性质和结构行为。选择钛、锆和铪二茂二氯化物与三当量的二苄基二硫代氨基甲酸钠反应合成了五种未见报道的七配位配合物,讨论了产物的光谱性质和配位结构。  相似文献   
134.
Rate constants (k's) of the thermal cyclodimerization of ten meta-substituted trifluorostyrenes (m-Y-TFS's) have been measured in the temperature range 110–160°C. On the basis of these k's and the σmb values derived from 19F NMR data the spin-delocalization substituent constant σ˙m values of these ten meta-substituents have been calculated. The averaged σ˙m values are: m-Et, 0.09; m-t-Bu, 0.11; m-F, 0.03; m-Cl,?0.05; m-Br, 0.12: m-CF3, ?0.07; m-OMe, 0.10; m-NO2, ?0.002; m-CN, 0.11 and m-CO2Me, 0.08. Both the smallness of these values and the nonexistence of correlation between Hammett-Type polar σX and these σ˙m values support our belief that the σj?J approach is reliable and trustworthy.  相似文献   
135.
相转移催化合成增塑剂BBP和水杨醛的研究   总被引:5,自引:0,他引:5  
相转移催化合成增塑剂BBP和水杨醛的研究郭锡坤,高文华,曾东宇(汕头大学化学系,汕头515063)关键词相转移催化,季铵盐,聚乙二醇,邻苯二甲酸丁苄酯,水杨醛,增塑剂邻苯二甲酸丁苄酯(增塑剂BBP)是一种优良的增塑剂.邻羟基苯甲醛(水杨醛)不仅是重要...  相似文献   
136.
The conversion of phosphoenolpyruvate (PEP) to phosphonopyruvate (P-pyr) is catalyzed by PEP mutase via a dissociative mechanism. In this work, we investigate the uncatalyzed reaction using ab initio methods, density functional theory, and the semiempirical MNDO/d method. Comparisons of geometries and relative energies of stationary points (minima and transition states) with density functional results indicate that the semiempirical method is reasonably accurate. Solvent effects are examined using implicit solvent models, including the recently extended smooth conductor-like screening model. Due to the large negative charge carried by the system, solvation is found to drastically alter the location and energy of stationary points along the dissociative reaction pathways. The influence of substituting a nonbridging phosphoryl oxygen by sulfur (thio effects) was also investigated. Implications of these results for the enzymatic reaction are discussed.  相似文献   
137.
Photocatalytic oxidation of water is a promising method to realize large-scale H2O2 production without a hazardous and energy-intensive process. In this study, we introduce a Pt/TiO2(anatase) photocatalyst to construct a simple and environmentally friendly system to achieve simultaneous H2 and H2O2 production. Both H2 and H2O2 are high-value chemicals, and their separation is automatic. Even without the assistance of a sacrificial agent, the system can reach an efficiency of 7410 and 5096 μmol g–1 h–1 (first 1 h) for H2 and H2O2, respectively, which is much higher than that of a commercial Pt/TiO2(anatase) system that has a similar morphology. This exceptional activity is attributed to the more favorable two-electron oxidation of water to H2O2, compared with the four-electron oxidation of water to O2.  相似文献   
138.
Unfractionated heparin (UFH), a naturally occurring anionic polysaccharide, is widely used as an anticoagulant agent in clinical practice. When overdosed or used in sensitive patients, UFH may cause various risks and a UFH neutralizer needs to be administered immediately to reverse heparinization. However, the most common UFH neutralizer, protamine sulfate, often causes various adverse effects, some of which are life-threatening. Herein, we designed a highly biocompatible, oligoethylene glycol functionalized guanidinocalixarene (GC4AOEG) as an antidote against UFH. GC4AOEG and UFH exhibited a strong binding affinity, ensuring specific recognition and neutralization of UFH by GC4AOEG in vitro and in vivo. As a consequence, UFH-induced excessive bleeding was significantly alleviated by GC4AOEG in different mouse bleeding models. Additionally, no adverse effects were observed during these treatments in vivo. Taken together, GC4AOEG, as a strategically designed, biocompatible artificial receptor with strong recognition affinity towards UFH, may have significant clinical potential as an alternative UFH reversal agent.

An oligoethylene glycol functionalized guanidinocalix[4]arene was developed as a safe antidote against heparin, via specific recognition and neutralization of heparin in vitro and in vivo.

Heparin sodium, often referred to as unfractionated heparin (UFH, also known as heparin), is a well-known anionic glycosaminoglycan consisting of long, helical, unbranched chains of repeating sulfonated disaccharide units (Fig. 1).1 It is currently a gold-standard life-saving drug to overcome blood coagulation by activating antithrombin-III to impede the coagulation process.2,3 Systemic heparinization is the most common anticoagulation procedure in surgical practice (e.g. open-heart surgery) and extracorporeal therapies such as kidney dialysis. At the end of surgery, excess heparin often needs to be deactivated by using a heparin neutralizer; otherwise patients have risks of low blood pressure and a slow heart rate, and may develop internal bleeding.4 Therefore, the neutralization of heparin has been a topic of significant research interest in the biomedical field.Open in a separate windowFig. 1Scheme of heparin reversal by GC4AOEG in the circulatory system.Protamine sulfate, the only FDA-approved neutralizer of UFH, possesses a highly positive charge density due to its polymeric nature and rich arginine residues. Thus, electrostatic interactions are the major driving force in the formation of a UFH–protamine complex, leading to the neutralization and deactivation of UFH.1,5 However, due to its non-specific interactions, protamine sulfate often causes various adverse effects such as bradycardia, hypotension and pulmonary hypertension, as well as allergic reactions including life-threatening anaphylactic reactions in some patients.5 When overdosed, protamine may further impair the intricate balance in the blood and cause coagulopathy.5–7 Given these issues, there has been a medical need for alternative, safe UFH neutralizers that can specifically counteract UFH without causing serious adverse effects.8Discovering and developing new heparin neutralizers has been a popular area of research.8,9 During the past two decades, a variety of different UFH neutralizers including small molecules,10 cationic polymers (e.g. polybrene),11–14 peptides,11,15 and nanoparticles16,17 have been designed and evaluated in vitro and/or in vivo. For instance, surfen, as a small-molecule antagonist of UFH, may electrostatically bind with UFH; however only modest neutralizing effects against UFH were observed in rats,10,18 likely attributed to the lack of strong, specific recognition. On the other hand, polycationic species, including polybrene19 and poly-dl-lysine,20 exhibited stronger binding with UFH and significant potential as UFH neutralization agents. However, toxicity was still a key concern of these species due to their intrinsic electrostatic interactions with red blood cells (RBC).21 Meanwhile, some UFH antagonists have achieved preliminary success in preclinical studies and even moved to clinical evaluations. For instance, ciraparantag (PER977), as a synthetic antidote against several anticoagulants, is currently being evaluated in phase II clinical trials.22 UHRA (Universal Heparin Reversal Agent), a synthetic multivalent dendrimer polymer in the form of nanoparticles with positively charged surfaces, can reverse the activity of all clinically available heparins and it is currently undergoing preclinical studies and will likely move to clinical investigations.23 However, the oligo- and poly-cationic nature of these species suggests their general tendency towards any negatively charged species, making them “universal” or function against several anticoagulants, implying their low specificity towards heparin.More recently, the sequestration and reversal of toxic agents by supramolecular host molecules have attracted increasing attention, and a typical example of clinical and commercial success is sugammadex, a carboxylated derivative of gamma-cyclodextrin that may specifically reverse the activity of non-depolarizing neuromuscular blocking agents.24 Inspired by this clinical success, several macrocycles were designed and synthesized to selectively bind UFH. For instance, Liu et al. synthesized amphiphilic multi-charged cyclodextrins (AMCD), and AMCD-assembly was utilized for selective heparin binding.16 Nitz et al. derivatized a cyclodextrin with amide and guanidino groups as a polycationic receptor to recognize and detect UFH.25 Kostiainen and co-workers studied cationic, quaternary ammonium functionalized pillar[5]arene because of its potential complexation with UFH.26 Additionally, cationic calixarene derivatives were designed for UFH binding and guanidinocalixarenes exhibited stronger binding affinity with UFH than their quaternary amine-functionalized counterparts.27,28 In spite of decent binding affinities and selective recognition of UFH, these macrocycles still possess various limitations such as non-specific toxicity induced mostly by cationic charges, which may disrupt cell membranes and induce blood coagulation.29,30An ideal UFH neutralizer should full-fill the following three requirements: (1) binding strongly towards UFH in a specific manner; (2) excellent biocompatibility and safety profile, and (3) a clearly defined molecular structure to facilitate batch-to-batch consistency. Thus far, none of the clinical UFH antagonists or previously reported candidates has fulfilled these conditions. Herein we designed an artificial receptor, an oligoethylene glycol functionalized guanidinocalixarene, GC4AOEG, by leveraging the asymmetrical structure of calixarene to strategically add guanidinium groups on one side and oligoethylene glycol (OEG) groups on the other side (Fig. 1). We anticipated that the guanidinium-enriched upper rim would bind strongly with UFH via salt bridges (charge-assisted hydrogen bonds).28,31 In addition, the biocompatible OEG-functionalized lower rim may help improve the water-solubility and biocompatibility of the host molecule.32,33GC4AOEG was synthesized in 5 steps starting from the maternal calix[4]arene (Fig. 2). Briefly, p-tert-butylcalix[4]arene 1 was alkylated with tosylate 234 to obtain compound 3 with a well-defined cone conformation, and replacement of the tert-butyl with nitro groups via an ipso-nitration reaction afforded compound 4.35 Subsequently, compound 4 was hydrogenated in the presence of SnCl2·2H2O, affording the tetramine derivative 5. Subsequently, compound 6 was obtained via a reaction between compound 5 and di-Boc-protected thiourea units. The removal of the protecting groups was achieved using SnCl4 in ethyl acetate, to yield the target GC4AOEG (the characterization of intermediates (Fig. S1 and S2) and GC4AOEG (Fig. S3) are in the ESI).Open in a separate windowFig. 2Synthetic route of GC4AOEG and fluorescence titrations. (A(a)) NaH, dry DMF, and 75 °C; (b) HNO3, AcOH, dry CH2Cl2, and r.t.; (c) SnCl2·2H2O, C2H5OH/AcOEt (1 : 1, v/v), and reflux; (d) 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, Et3N, AgNO3, dry CH2Cl2, and r.t.; (e) SnCl4, AcOEt, and r.t. (B) Direct fluorescence titration of 0.5 μM EY with different concentrations of GC4AOEG (up to 13.8 μM) in HEPES buffer (10 mM, pH = 7.4), and λex = 517 nm. (Inset) The associated titration curve at λem = 537 nm and best fit according to a 1 : 1 binding stoichiometry. (C) Competitive fluorescence titration of GC4AOEG·EY (4.0/0.5 μM) with UFH (up to 8.4 μM in the concentration of monomer units of UFH), and λex = 517 nm. (Inset) The associated titration curve at λem = 537 nm and best fit according to a n : 1 competitive binding model, where n = 0.88.The binding affinity between GC4AOEG and UFH was firstly investigated via a competitive titration approach. In this paper, we defined the repeated disaccharide unit as the UFH monomer unit, and the UFH concentration in this paper is the UFH monomer unit concentration. Eosin Y (EY) was selected as the reporter dye, owing to its strong complexation with GC4AOEG and the drastic fluorescence quenching after complexation. The equilibrium association constant (Ka), between GC4AOEG and EY, was determined by direct fluorescence titration and fitted as (2.37 ± 0.12) × 105 M−1 with 1 : 1 binding stoichiometry (Fig. 2B). The displacement of EY from GC4AOEG·EY by gradual addition of UFH resulted in the recovery of the intrinsic emission of EY. The best-fitting of the competitive titration model afforded ca. 1 : 1 binding stoichiometry between GC4AOEG and each monomer unit of UFH, as well as an ultrahigh binding affinity Ka of (1.25 ± 0.13) × 107 M−1 (Fig. 2C).For in vitro analysis of the effectiveness of GC4AOEG against UFH, the activated partial thromboplastin time (aPTT) assay was conducted. The result (Fig. S8) indicates that one equivalent of GC4AOEG (to UFH monomer) fully neutralized UFH, similar to protamine. Very importantly, it is obvious that protamine alone negatively influenced the aPTT time. In contrast, GC4AOEG alone did not affect the clotting time, suggesting that GC4AOEG can specifically bind with UFH directly with minimal side influences. The coagulation factor X levels in the plasma analyzed via the enzyme-linked immunosorbent assay (ELISA) further confirmed the safety and reversal effect of GC4AOEG towards UFH (Fig. S9).Next, the biocompatibility of GC4AOEG was investigated in vitro. As an alkyl derivative of guanidinocalixarene, GC4A-6C (Fig. S4 and S5), which has a similar number of carbons (hexyl groups) at the lower rim to that of GC4AOEG, was also synthesized and examined in this study for comparative purposes. As shown in Fig. 3A and B, GC4AOEG (up to 200 μM) showed remarkably low cytotoxicity in several cell lines via MTT assays, in dramatic contrast to the relatively high cytotoxicity of GC4A-6C (Fig. 3C and D). The cellular toxicity of GC4A-6C was consistent with previous literature.36 In addition, alkyl derivatives of calixarene were generally more toxic than those without alkyl chains,37 likely attributed to their amphiphilic properties that may facilitate cell membrane disruption.38–40 The results suggested that the much-improved safety profile of GC4AOEG was attributed to oligoethylene glycol functionalization. Meanwhile, it is well known that cationic polymers or oligomers often show poor biocompatibility in the circulation system due to their non-selective binding to negatively charged RBC, resulting in RBC aggregation or hemolysis.41 Therefore, hemolysis and hemagglutination assays were conducted according to a method previously reported,42,43 with experimental details described in the method. The percent hemolysis of GC4A-6C (25, 50, 100 and 200 μM, respectively) was over 90%, which would limit its application in the circulatory system (Fig. S6), as a hemolysis ratio below 5% is considered safe.44 Conversely, GC4AOEG exhibited nearly negligible (less than 3%) hemolytic activity at concentrations of up to 200 μM, and no agglutination was visualized during incubation with RBC (Fig. 3F), implying that OEG functionalization at the lower rim reduced non-specific interactions with the RBC membrane, resulting in less disturbance of the membrane structure and function or cellular aggregations.Open in a separate windowFig. 3Biocompatibility study in cell lines and RBC. Cell viabilities of (A, C) 4T1 and (B, D) 293T, cells treated with different concentrations of GC4AOEG or GC4A-6C for 24 h. Each data point represents the mean ± S.E.M. from a set of experiments (n = 4). (E, G) Hemolysis test of GC4AOEG at different concentrations (NC = negative control; PC = positive control). Each data point represents the mean ± S.E.M. from a set of experiments (n = 3). (F) Agglutination test of RBC incubated with GC4AOEG at 2.0% hematocrit in normal saline.Inspired by the above findings, we further examined whether GC4AOEG may reverse bleeding in different mouse bleeding models under heparinization (with the experimental details described in the method, and the standard curve for the quantification of blood loss volume is showed in Fig. S7),45 with both the total time of bleeding and total volume of lost blood evaluated for each model. As a proof of concept, 200 U kg−1 UFH and 2.245 mg kg−1 GC4AOEG (molar ratio of GC4AOEG and each monomer unit of UFH = 1 : 1) were respectively used, as representative doses in the study and the dose of UFH was based on a literature report.46 In a mouse tail transection model as an external bleeding model, as shown in Fig. 4A–C, after tail transection, the bleeding time and blood loss volume for mice treated with normal saline were 58.9 ± 10.7 min and 72.2 ± 15.8 μL, respectively. As expected, treatment with UFH increased the bleeding time and blood volume to 121.5 ± 20.2 min and 264.0 ± 43.6 μL, respectively. In contrast, the bleeding time was dramatically reduced down to the blank control level, when the mice were treated with GC4AOEG at the same time of, or 30 s after, i.v. administration of UFH (53.8 ± 11.4 min and 89.0 ± 13.3 min, respectively). Accordingly, the blood loss volume of mice successively treated with UFH and GC4AOEG (1 : 1 ratio) reached the control level (72.6 ± 14.3 μL), indicating that the strong binding affinity between GC4AOEG and UFH ensured their recognition in vivo. Of note, there was no significant difference between the GC4AOEG treated group (without heparinization) and the saline treated group, suggesting a decent safety profile of the artificial receptor.Open in a separate windowFig. 4Reversal efficacy in in vivo mouse models. (A–C) Mouse tail transection model. (A) Scheme of the mouse tail transection model. (B) Total time of bleeding and (C) blood loss volume. (D–F & J) Mouse liver injury model. (D) Scheme of the mouse liver injury model. (E) Total time of bleeding and (F) blood loss weight. (J) Pictures exhibiting bleeding in liver injury before and after treatment. (G–I & K) Mouse femoral artery model. (G) Scheme of the mouse femoral artery model. (H) Total time of bleeding and (I) blood loss weight. (K) Pictures exhibiting bleeding in the femoral artery before and after treatment. All of those models were i.v. administration with normal saline (control), GC4AOEG (2.245 mg kg−1), or UFH (200 U kg−1) without and with GC4AOEG (2.245 mg kg−1, 1 : 1 molar stoichiometry of GC4AOEG and the monomer unit of UFH), and UFH–GC4AOEG 1 : 1 successively (GC4AOEG at a dose of 2.245 mg kg−1 30 s after UFH administration) respectively were quantified. Data presented are the mean ± S.E.M. (n = 6). *p < 0.05, ****p < 0.001, and ns represents “no significant difference” between the experimental group and the control group.In addition to external bleeding, internal bleeding such as liver injury model (Fig. 4D) was established in mice, and GC4AOEG''s reversal of UFH was further evaluated in vivo. Mice were i.v. administered with normal saline (control), GC4AOEG (2.245 mg kg−1), or UFH (200 U kg−1) without and with GC4AOEG (2.245 mg kg−1), and successive UFH–GC4AOEG 1 : 1 (30 s in between), respectively. In 2 minutes, the abdomen was surgically opened to expose the liver. A wound of 0.5 cm length and 2 mm depth, in the left lobe of the liver, was created. Considerable bleeding was immediately observed in the UFH treatment group (Fig. 4J), with the total bleeding time lasting for 450.5 ± 46.8 s, and the total blood loss of 571.0 ± 35.0 mg, in contrast to 143.7 ± 14.7 s total bleeding time and 238.0 ± 45.0 mg total blood loss observed in the saline treated group. Interestingly, the UFH–GC4AOEG treated group showed no significant difference from the normal saline treated group. To simulate the clinical use scenario, GC4AOEG was injected after UFH''s administration, and significantly reduced bleeding (from both time and volume perspectives) was observed, suggesting effective inhibition of the adverse effects of UFH, by GC4AOEG (Fig. 4E and F). GC4AOEG alone (without heparinization) did not exhibit any hematological toxicity in this model. To further evaluate the inhibitory effects of GC4AOEG against UFH in a preclinical model, a more serious internal bleeding model, femoral artery bleeding mouse model, was employed, and the treatment plan followed the previous two models described as above. Upon administration, the skin of the right leg and the overlying muscles were removed to expose the femoral artery and sciatic nerve. After an open injury at the middle segment of the femoral artery was created with a surgical scissor, blood gushed out immediately from the injured site (Fig. 4G and K). As shown in Fig. 4H and I, the longest average bleeding time (16.0 ± 1.9 min) and blood loss weight (103.8 ± 16.9 mg) were observed in the UFH treatment group of mice, in dramatic contrast to the bleeding time and blood loss of 3.9 ± 0.4 min and 24.7 ± 4.5 mg, respectively, in the normal saline treated group of mice. A bleeding time of 3.6 ± 0.4 min and blood loss of 20.8 ± 7.4 mg were recorded in the UFH–GC4AOEG treatment group. When UFH and GC4AOEG (at 1 molar equivalent) were successively injected, a bleeding time of 5.3 ± 0.7 min and blood loss of 27.7 ± 5.8 mg were noted, suggesting the significant reversal effects of GC4AOEG on UFH. Collectively, in all of the three bleeding models including internal and external bleeding models, i.v. administration of GC4AOEG significantly reversed UFH-induced excessive bleeding in external and internal injuries. More importantly, GC4AOEG alone exhibited negligible hematological activity, unlike other previously reported cationic small molecules, polymers, oligomers and macrocycles.Furthermore, in order to further verify the safety profile of GC4AOEG at the effective dose in vivo, acute toxicity evaluation was performed in a mouse model. After the i.v. injection of GC4AOEG in mice at a dose of 2.245 mg kg−1 (i.v. injection of normal saline as the control group), the body weight, behaviors, and overall survival of the treated mice were monitored every day for 3 weeks. All the treated mice remained alive and showed normal behaviors, as well as normal body weight evolvement similar to that of the control group (Fig. 5A). On day 21 post administration, mice were euthanized for blood and organ samples were harvested (for details see the method). The organ indexes of representative major organs including the heart, liver, spleen, lungs, and kidneys isolated from the GC4AOEG treated mice were comparable to those of the mice administered with normal saline, with no significant differences observed (Fig. 5B). Hematological parameters such as the counts of whole blood cells (WBCs), red blood cells (RBCs), platelets (PLTs) and hemoglobin (HGB) (Fig. 5C), as well as the serum concentrations of liver and kidney function biomarkers including blood urea nitrogen (BUN), creatinine (crea), urea alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were all analyzed thoroughly (Fig. 5D and E). These results indicated that the hematological parameters, renal and hepatic functions of the mice treated with GC4AOEG were comparable with those of the mice in the normal saline treated group. Moreover, histopathological examinations of the major organs of the GC4AOEG treated mice showed normal microstructures comparable with those of the control group (Fig. 5F). Collectively, these results suggested that the i.v. administration of GC4AOEG at the therapeutic dose is safe.Open in a separate windowFig. 5Preliminary acute toxicity evaluations on GC4AOEG. (A) Weight changes of mice after i.v. administration with a single dose of GC4AOEG. (B) Major organ indexes of the mice on day 21 post-administration with GC4AOEG. (C) Hematological parameters of the blood samples collected from the mice on day 21 after i.v. administration of GC4AOEG. (D) Renal and (E) hepatic functional biomarkers in the blood samples collected from the mice on day 21 after i.v. administration of GC4AOEG. Data are presented as mean ± S.E.M.; n = 6 for each group. (F) H&E histopathological analysis of the major organs from mice sacrificed 21 days after being injected with saline and GC4AOEG (2.245 mg kg−1). Scale bar = 100 μm.  相似文献   
139.
黄雪红  许国强 《合成化学》2002,10(2):135-139
采用沉淀聚合法合成了聚(丙烯酰胺-丙烯酸十四酯),聚(丙烯酰胺-丙烯酸十六酯)和聚(丙烯酰胺-丙烯酸十八酯),重点讨论了共聚物中疏水基团数量及疏水基团链长对增稠性能的影响。采用凯达尔定氮法和动态热分析(DMTA)测定了共聚物的组成及玻璃化温度。  相似文献   
140.
A new potential tetradentate ligand, 1,4-bis(N-1-methylimidazol-2-ylmethyl)-1,4-diazacycloheptane (l), together with its CuII complex [CulCl]ClO4 (1), has been reported. The crystal structure of 1, determined by single-crystal X-ray analysis, shows that it is in chiral P212121 space group. The CuII centre is penta-coordinated in square pyramidal geometry and the diazacycloheptane (DACH) ring adopts normal boat configuration. The most striking feature of this complex is the formation of a 3D network bridged through the C-H?Cl hydrogen bonds with the perchlorate anions in the cavities, and stabilized via π-π stacking interactions along the a-direction. The solution behaviour of 1 has been further investigated by UV/Vis and ESR techniques.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号